Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ ...
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...
The drug, which is called suzetrigine and will be sold under the brand name Journavx, is the first new type of pain medicine approved by the agency in more than 20 years. Dr. Jacqueline Corrigan ...
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results